Pleural and Peritoneal Mesothelioma Combination Can Be Managed

A patient diagnosed with pleural and peritoneal mesothelioma today can survive well beyond expectations, provided personalized treatment can be found at a specialty center. Research from the Columbia University Medical Center in New York City has shown that despite the poor prognosis typically accompanies this rare diagnosis, patients still can thrive. “This is an understudied, and poorly understood, group of patients that often is just written off,” surgical oncologist Dr. Michael Kluger at Columbia told The Mesothelioma Center at Asbestos.com. “But we’ve shown a meaningful survival.” Kluger, who specializes in peritoneal mesothelioma, is co-author of a recent, single-center study. The cohort included 50 patients spanning 21 years who were treated for malignant mesothelioma in the thoracic (pleural) and abdominal (peritoneal) cavities at the New York Presbyterian Hospital/Columbia Medical Center. Annals of Surgical Oncology published the study in its January 2020 issue. Find Top Cancer Centers Near You State: Please Select a State AlabamaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIllinoisIndianaKansasLouisianaMaineMarylandMassachusettsMichiganMinnesotaMissouriMontanaNebraskaNevadaNew JerseyNew YorkNorth CarolinaOhioOregonPennsylvaniaSouth CarolinaTennesseeTexasUtahVermontVirginiaWashingtonWashington D.C.Wisconsin Dia...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Malignant pleural mesothelioma (MPM) is a rare but aggressive cancer. The long latency from asbestos exposure to MPM development, as well as the absence of early symptoms, lead to late diagnosis and very poor prognosis, with a life expectancy of 9-18 months from diagnosis [1]. Only a small number of patients is suitable for multimodal therapy, including surgery, and the majority of patients receive palliative chemotherapy.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor originating from mesothelial cells. It is associated with exposure to asbestos, mainly occupational, rarely environmental or domestic. Diagnosis is usually made at an advanced stage because symptoms are non-specific and late. The management of this tumor is challenging and outcome is poor. Therapeutic strategies are mainly based on surgery with curative intent or palliative cytotoxic chemotherapy. Few patients are candidates for surgery which must necessarily take into account numerous factors (i.e.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
The Princess Margaret Cancer Center in Toronto has moved from SMART to SMARTER with the recent launch of its latest clinical trial for pleural mesothelioma patients. SMARTER is the acronym for Surgery for Mesothelioma After Radiation Therapy using Extensive pleural Resection, which also describes the latest clinical trial. The phase I clinical trial is an unconventional approach to treatment of mesothelioma: Find the maximum tolerated dosage of hypofractionated radiation to stimulate the immune system before aggressive surgery. It comes on the heels of the SMART protocol, which stands for Surgery for Mesothelioma After Rad...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The International Mesothelioma Interest Group (IMIG) ’s biennial conference in Ottawa, Canada held a session that addressed the contributions of Radiation Oncology to the treatment of this disease. While the contribution of hemithoracic radiation to the local control of this disease has held much interest, this session explored the application of ra diation in other clinical scenarios. The ideas presented around the application of palliative approaches to radiation delivery that improve symptom burden in this disease are being addressed in a randomised trial in the United Kingdom.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
The International Mesothelioma Interest Group (IMIG) ’s biennial conference in Ottawa, Canada held a session that addressed the contributions of Radiation Oncology to the treatment of this disease. While the contribution of hemithoracic radiation to the local control of this disease has held much interest, this session explored the application of ra diation in other clinical scenarios. The ideas presented around the application of palliative approaches to radiation delivery that improve symptom burden in this disease are being addressed in a randomised trial in the United Kingdom.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Malignant pleural mesothelioma (MPM) is an aggressive and invariably fatal cancer of the pleural surface that is associated with asbestos exposure [1]. MPM is usually detected at an advanced stage, therefore treatment options are limited to systemic chemotherapy with cisplatin and pemetrexed as the mainstay of palliative treatment for most patients [2]. Prognosis is generally poor for MPM, with a median survival of 12 months in patients treated with pemetrexed and cisplatin chemotherapy [3] but can be very variable, with around 5% of patients surviving more than 5 years [4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Doctors at the Princess Margaret Cancer Center in Toronto are studying the use of hypofractionated radiation to increase the effectiveness of immunotherapy for patients with mesothelioma. They are expected to launch soon a clinical trial that will add an immunotherapy combination to the high-dose radiation and aggressive surgery mix that has been so successful in Toronto. “There are a lot of questions that still need to be answered, but if I was a betting man, I’d lay odds on it [working well],” Dr. John Cho of the cancer center’s clinical research unit, told The Mesothelioma Center at Asbestos.com....
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Aggressive surgery for the treatment of malignant pleural mesothelioma is being underutilized, costing patients significant survival time, according to a recent study. Researchers found mesothelioma patients from all three histological subtypes — epithelioid, biphasic and sarcomatoid — can benefit from surgery, despite a reluctance to perform it today. The National Comprehensive Cancer Network (NCCN), a nationwide alliance of leading cancer centers, encourages surgery only for epithelioid patients. This eliminates the option for almost 40 percent of those diagnosed with mesothelioma. “Surgery is underutil...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer, which is often causally associated with asbestos exposure. Given the long latency period between asbestos exposure and MPM development and because asbestos is still being used in some countries, MPM will remain a global health issue for decades to come [1]. Although improvements in outcome have been observed with the advent of -palliative- chemotherapy, overall survival of patients plateaus at a median of one year [2]. Amongst others, this dismal prognosis can be attributed to difficulties in (early) diagnosis, lack of effective treatment and treatment monitoring.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
A University of Michigan and Veterans Affairs research team has developed a novel, personalized lung cancer screening tool that accounts for past asbestos exposure. Asbestos exposure is best known as the primary cause of mesothelioma, but it also significantly increases the chance of developing lung cancer. Adding asbestos to the lung-cancer screening tool also should help identify mesothelioma in its earliest stages, when it is most treatable. Mesothelioma is not usually diagnosed until it has progressed into stage 3 or stage 4, when treatment is more palliative than potentially curative. The tool is designed to better i...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Baylor College of Medicine | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Clinical Trials | Databases & Libraries | Environmental Health | Epidemiology | Fruit | Hospitals | Learning | Legislation | Lung Cancer | Mesothelioma | National Institutes of Health (NIH) | Palliative | Palliative Care | Study | Sweden Health | Texas University | Universities & Medical Training | University of Maryland | USA Health | Women | Yale